Lv21
116 积分 2023-09-27 加入
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype
2小时前
已完结
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
4小时前
已完结
Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer
7天前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
7天前
已完结
From nuclear to extracellular PTEN: Multiple roles in tumor suppression and immune modulation
8天前
已完结
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer
12天前
已完结
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)
12天前
已完结
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study
21天前
已完结
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
26天前
已完结
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
26天前
已完结
皖公网安备34019202002308
